NCT02260661View on ClinicalTrials.gov

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Advanced Solid MalignanciesBreast Cancer - ER+, HER2 -Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions
DRUG

AZD8835

AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components

DRUG

AZD8835

AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components

DRUG

AZD8835 in combination with fulvestrant

AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.

DRUG

AZD8835 in combination with fulvestrant

AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy

Trial Locations (9)

Unknown

Research Site, Denver

Research Site, Greenville

Research Site, Nashville

Research Site, Houston

Research Site, Milwaukee

Research Site, Cambridge

Research Site, London

Research Site, Manchester

W1G 6AD

Sarah Cannon Research Institute, United Kingdom, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT02260661 - Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter